[Form 4] Microbot Medical Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Microbot Medical Inc. director Aileen Ptucha Stockburger received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and are scheduled to expire on April 1, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Stockburger Aileen Ptucha
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,000 shares (Direct)
Footnotes (1)
Key Figures
Options granted: 10,000 options
Exercise price: $2.37 per share
Underlying shares: 10,000 shares
+3 more
6 metrics
Options granted
10,000 options
Stock Option (Right to Buy) granted April 1, 2026
Exercise price
$2.37 per share
Conversion or exercise price for options
Underlying shares
10,000 shares
Common stock underlying the option grant
Total derivative holdings after grant
10,000 options
Total shares following transaction for this option award
Grant date
April 1, 2026
Option grant and exercise date
Expiration date
April 1, 2036
Option expiration
Key Terms
Stock Option (Right to Buy), grant/award acquisition, Common Stock, par value $0.01 per share, Form 4
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
grant/award acquisition financial
"transaction_action: "grant/award acquisition""
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.